Treatments & Interventions
Daunorubicin hydrochloride
substance
Doxorubicin hydrochloride
substance
Idarubicin hydrochloride
substance
Daunorubicin citrate
substance
Gemtuzumab ozogamicin
substance
Idarubicin
substance
Daunorubicin
substance
Doxorubicin
substance
Mitoxantrone
substance
Etoposide
substance
Cyclophosphamide
substance
Mitoxantrone hydrochloride
substance
Daunorubicin hydrochloride liposome
substance
Daunorubicin liposome
substance
Etoposide phosphate
substance
Daunorubicin citrate liposome
substance
Cyclophosphamide monohydrate
substance
Enasidenib
substance
Enasidenib mesylate
substance
Midostaurin
substance
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
Related Conditions
Quick Facts
- SNOMED CT
- 91861009
- UMLS CUI
- C0023467
- Fully Specified Name
- Acute myeloid leukemia (disorder)
- Specialists
- 0
- Diagnostic Biomarkers
- 0
- HPO Phenotypes
- 1
- Known Treatments
- 20
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.